Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: old 'n cranky who wrote (11885)	2/7/2019 1:52:17 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

I believe that the company very likely will not live long enough for this issue of an onerous 15% royalty ever to become a real financial event. But it's a bit in my nature to look ahead for the next risk. In my mind, the biggest risks are (listed chronologically): Dr. Diwan managing the company with huge conflicts of interest and lacking the skills necessary to effectively run this business The lack of working capital The questionable viability of the enterprise as far as costs and revenues TheraCour (through its markups and royalty charges) starving NNVC for the working capital necessary to grow Sadly, I believe the onerous and unfair licensing agreements impact all three more-near-term risks: They change the way Diwan thinks and acts, pushing for more compensation without due regard for the success of the company and its shareholders. They scare off potential investors who, if they're smart, want nothing to do with the onerous and ridiculous licensing agreements the current common shareholders are saddled with. Diwan has structured this enterprise to be unnecessarily expensive to NNVC, and to remove all negotiating power of NNVC between it and TheraCour by putting control of R&D and production with TheraCour. That's why I think this issue is important to address today...